Vesicular Stomatitis Virus-Simian Retrovirus Type 2 Vaccine Protects Macaques from Detectable Infection and B-Cell Destruction
被引:5
|
作者:
Gautam, Rajeev
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Gautam, Rajeev
[1
]
Iyer, Arun
论文数: 0引用数: 0
h-index: 0
机构:
Louisiana State Univ, Sch Vet Med, Div Biotechnol & Mol Med, Baton Rouge, LA 70803 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Iyer, Arun
[3
]
Hunter, Meredith
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Hunter, Meredith
[1
]
Das, Arpita
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Das, Arpita
[1
]
Williams, Tessa
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Natl Primate Res Ctr, Div Vet Med, Covington, LA 70433 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Williams, Tessa
[2
]
Dufour, Jason
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Natl Primate Res Ctr, Div Vet Med, Covington, LA 70433 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Dufour, Jason
[2
]
Apetrei, Cristian
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Apetrei, Cristian
[1
]
Kousoulas, K. Gus
论文数: 0引用数: 0
h-index: 0
机构:
Louisiana State Univ, Sch Vet Med, Div Biotechnol & Mol Med, Baton Rouge, LA 70803 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Kousoulas, K. Gus
[3
]
Marx, Preston A.
论文数: 0引用数: 0
h-index: 0
机构:
Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USATulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
Marx, Preston A.
[1
]
机构:
[1] Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
[2] Tulane Natl Primate Res Ctr, Div Vet Med, Covington, LA 70433 USA
[3] Louisiana State Univ, Sch Vet Med, Div Biotechnol & Mol Med, Baton Rouge, LA 70803 USA
Natural infection with simian retrovirus (SRV) has long been recognized in rhesus macaques (RMs) and may result in an AIDS-like disease. Importantly, SRV infections persist as a problem in recently imported macaques. Therefore, there is a clear need to control SRV spread in macaque colonies. We developed a recombinant vesicular stomatitis virus (VSV)-SRV vaccine consisting of replication-competent hybrid VSVs that express SRV gag and env in separate vectors. The goal of this study was to assess the immunogenicity and protective efficacy of the VSV-SRV serotype 2 vaccine prime-boost approach in RMs. The VSV-SRV vector (expressing either SRV gag or env) vaccines were intranasally administered in 4 RMs, followed by a boost 1 month after the first vaccination. Four RMs served as controls and received the VSV vector alone. Two months after the boost, all animals were intravenously challenged with SRV-2 and monitored for 90 days. After the SRV-2 challenge, all four controls became infected, and viral loads (VLs) ranged from 106 to 108 SRV RNA copies/ml of plasma. Two animals in the control group developed simian AIDS within 7 to 8 weeks postinfection and were euthanized. Anemia and weight loss were observed in the remaining controls. During acute infection, severe B-cell depletion and no significant changes in T-cell population were observed in the control group. Control RMs with greater preservation of B cells and lower VLs survived longer. SRV-2 was undetectable in vaccinated animals, which remained healthy, with no clinical or biological signs of infection and preservation of B cells. Our study showed that the VSV-SRV vaccine is a strong approach for preventing clinically relevant type D retrovirus infection and disease in RMs, with protection of 4/4 RMs from SRV infection and prevention of B-cell destruction. B-cell protection was the strongest correlate of the long-term survival of all vaccinated and control RMs.